The first and only enzyme replacement therapy for the treatment of a very rare and complex blood disorder has been approved by the US Food and Drug Administration.
The Pistoia Alliance is a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D. It has just announced its four new strategic priorities made up of global pharma and tech representatives to deliver new project...
Cynthia Pussinen knew she wanted to work in STEM fields by the time she was a teenager, she received a full scholarship to study nuclear engineering but after two years changed to chemistry for her major.
Owlstone Medical's exegenous volatile organic compound (EVOC) breath test can reveal signs of liver cirrhosis and portal hypertension, a study has found.
A partnership between clinical research technology company uMotif and cognitive science company, Cogstate Limited, will see the companies continue existing work that includes a major phase 2 clinical trial of a psychedelic therapeutic.
Excessive costs cost and time to market in clinical trials could soon be eliminated thanks to the addition of a patient access store (PAS) to Phesi's trial accelerator platform.
myTrialsConnect, a research community powered by artificial intelligence (AI) has been launched following a partnership between Elligo Health Research and Avallano.
Executive director of Medical Research Network's (MRN's) digital health, Edward Triebell, joined OSP for a Q&A where he shared some interesting shifts and statistics about digital trends in clinical research.
Vice president and global head of bioanalytical and central lab services, Lan Li has always found doctors fascinating. Their ability to save lives and give second chances set her on her career path, but it was recognizing there were still so many unmet...
A not-for-profit organization, Medicines Development for Global Health (MDGH), that develops medicines for neglected diseases in low- and middle-income countries, will benefit from support from contract research organization (CRO), Phastar.
The US Food and Drug Administration (FDA) has approved a potassium-competitive acid blocker (PCAB) as a new treatment for the healing of all grades of erosive esophagitis.
Unfortunately, more than 700 rare diseases affect more than 30 million people in the US alone and with many of them being life threatening, it is still a concern that most still do not have treatments.
By By Michael Braunagel, managing director, Actigen
Enzyme replacement therapy (ERT) made its debut in 1991, heralding a breakthrough in medical science for individuals and families grappling with rare diseases stemming from single gene mutations.
OSP had a quickfire interview with Rebecca Starkie, senior global patient engagement director, at Advanced Clinical where she explains the challenges faced by rare disease patients - and suggests ways to improve.
Element Biosciences, Inc., will share news of its sequencing methodology and host a workshop on higher accuracy sequencing for improved variant detection in Washington DC from today.
Clinical stage pharma company PharmaKure believe their combined drug targeting amyloid deposits associated with Alzheimer’s Disease can bring quality of life to patients.
Matteo Lai was part of a panel at DPharm in Boston this year, it was called working together to accelerate the adoption of digital biomarkers in clinical trials.
Dave Hine is the senior director of sales engineering at Greenphire. He has been reflecting on his time at DPharm and the collaborative approach to life sciences.
Physics-powered GenAI Biotech, Gero, announced yesterday (October 18) that it had closed a $6 million series A extension round with funding from Melnicheck Investments and other investors.
The Gen AI revolution promises to redefine various industries, with the life sciences sector at the forefront of this transformation. OSP had the chance to speak to Tarun Mathur, CEO at Indegene, who was keen to allay many of the fears those in the industry...
Emma Harvey is global head of medical affairs at F2G Ltd, a UK and Austria based biotech where she is responsible for the global medical and commercial strategies for a novel antifungal drug for serious systemic infections, in clinical development.
AstraZeneca’s supplemental new drug application (sNDA) for lead lung cancer drug Tagrisso (Osimertinib) in combination with chemotherapy has been accepted and granted priority review in the US.
Technology company, Medable Inc., offering services for modern clincal trials has joined forces with Pluto Health, a smart care coordination services company offering a health coordination platform.
The heavy burden on immediate family members with neurodegenerative diseases and their caregivers, was the initial driving force to study pharmacy for Andrea Pfeifer.
Complete clinical trials solution company, Hawthorne Effect, announced today (October 10) it had successfully recruited more than 1,000 patients in 48 states plus Hawaii for a study to qualify the prevalence of valvular heart disease (VHD).
The unique glutamatergic mechanism of action in Newron Pharmaceuticals’ investigational new drug can potentially produce a long-lasting antipsychotic response in patients with TRS, and the benefits will accrue over time.
A new patient-first service that will support sponsors and sites accelerate the development of their therapies has been launched by Innovative Trials yesterday (October 9).
A new generative artificial intelligence (AI) tool has been launched by H1, a global healthcare data company and will have a 'profound impact on clinical trial diversity'.
A 15-year partnership between Medidata, a Dassault Systèmes company, and the National Cancer Institute (NCI) has been extended by five years. The NCI is part of the National Institutes of Health.
Veradigm Inc. and Holmusk have announced the next step in their strategic collaboration helping them move closer to their vision of creating a single source of truth for behavioral health.
Novartis announced today (October 2) that it is excited about positive top-line results from its study into iptacopan, a drug to treat IgA nephropathy (IgAN).
A study to evaluate the effect of seladelparm, a small molecule treatment by CymaBay Therapeutics, Inc. on patients with cirrhosis was announced this month (September 21).
